Novartis receives EU approval for Votubia®, the first medication to treat children and adults with SEGA associated with TSC
* Reuters is not responsible for the content in this press release.
Thu Sep 8, 2011 1:15am EDT
Novartis International AG / Novartis receives EU approval for Votubia®, the first medication to treat children and adults with SEGA associated with TSC . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the...
WASHINGTON (AFP) - The US Food and Drug Administration said Monday it had approved a drug currently used in patients with advanced kidney cancer to treat brain tumors caused by a rare genetic disease.
Everolimus, which is marketed under the name Afinitor by Novartis, was approved to treat tumors caused by the genetic condition tuberous sclerosis that cannot be treated with surgery, the FDA said in a statement....
Phase III Study Shows Novartis Drug Afinitor® More Than Doubles Time Without Tumor Growth In Advanced Pancreatic NET Patients
Article Date: 03 Jul 2010 - 1:00 PDT
Novartis Pharmaceuticals Corporation ("Novartis") announced that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine...
Everolimus demonstrated disease control, tumor shrinkage in previously treated advanced gastric cancer
HemOnc today
Posted April 16, 2010
Everolimus monotherapy in previously treated patients with advanced gastric cancer was well-tolerated and demonstrated promising disease control, according to the findings of a phase-2 trial.
Researchers analyzed data from 53 patients assigned 10 mg per day everolimus (Afinitor, Novartis) taken orally until tumor progression,...
* Watchdog recommends against Afinitor, Tasigna and Sprycel
* Limited data to back benefits of three pricey drugs - NICE
LONDON, Feb 9 (Reuters) - Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG (NOVN.VX) and one from Bristol-Myers Squibb Co (BMY.N) being used within the state-run health service.
The National Institute for Health and Clinical Excellence (NICE) said...
